ASH 2022 Annual Meeting – Insights Into Major Diffuse Large B-cell Lymphoma (DLBCL) Abstract and Breakthroughs
Dec 09, 2022
Blood cancers have seen tremendous advancements in the past few years owing to the dedication of the researchers who are putting their endless efforts just to bring innovation into the lives of suffering patients. These experiments and their upshots are always brought to us through various platforms, the American Society of Hematology (ASH) being one of them.
The 64th ASH Annual Meeting and Exposition is a four-day premier event in malignant and non-malignant hematology, scheduled to start on December 10, 2022. Like every year, the ASH conference shared new abstracts from a robust portfolio and pipeline of advanced therapeutic platforms in cancer and other blood disorders, highlighting the impact of our bold science in research. On this note, Delveinsight has listed a few major abstracts for diffuse large B-cell lymphoma (DLBCL).
The key abstracts have been summarized in the table below:
Downloads
Click Here To Get the Article in PDF
Recent Articles
- Major Highlights of ASH 2021 Annual Meeting: Stay abreast of the fresh developments!!
- Pioneering Progress: ZYNLONTA and Rituximab Combo Delivers Striking 96% Overall Response in Relap...
- Meeting the Unmet: Nonalcoholic Steatohepatitis (NASH)
- Which Countries Top the Chart in Global Pharmaceutical Market?
- FDA Approves AstraZeneca’s Enhertu; Bayer Wins FDA Approval for Prostate Cancer Therapy, Nubeqa; ...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Downloads
Article in PDF
Recent Articles
- TALVEY’s Versatility Shines: Key Insights from MonumenTAL-2 Study Illuminate Effective Stra...
- Snippet: M&A activities of big pharma’s will fuel CAR-T cell therapy
- Statistical Insight on Some Common Cancers
- EPCORE NHL-1 Trial Reveals Promising Response Rates for Investigational Follicular Lymphoma Thera...
- Biohaven’s trial ; GSK integrates; FDA Approval; Phase III trial
